earnings
confidence high
sentiment positive
materiality 0.60
Shattuck Labs Q2 net loss $21.5M; SL-172154 shows 67% ORR in HR-MDS trial
Shattuck Labs, Inc.
2024-Q2 EPS reported
-$0.79
revenue$2,724,000
- Net loss $21.5M ($0.42 per share) vs $21.3M ($0.50 per share) Q2 2023.
- Cash and investments $105.3M as of June 30, 2024, down from $117.2M a year ago.
- SL-172154 in frontline HR-MDS: 67% ORR, 58% CR/marrow CR rate; median OS not reached.
- Randomized Part D enrollment initiated in frontline HR-MDS (1:1:1 vs AZA alone).
- Cash runway into 2026, beyond Phase 1 trial results.